focus -WSS

focus

author：hotspot 2025-10-01 18:07:16 - browse：943

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The health care issue Democrats can’t solve: hospital reform

WSS

Key Senate panel to consider PBM, drug pricing reform package

Walensky prepares to leave CDC — and Congress — behind

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

As demand for Covid shots wanes, Moderna seeks its next success

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Medicare must police algorithms in Medicare Advantage, Dems say

Trump demands the U.S. pay no more for drugs than other countries … again

Anesthesiologist group: stop taking Ozempic before surgery

The cancer drug shortage isn’t new — and neither are the solutions

Trump demands the U.S. pay no more for drugs than other countries … again

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bill would allow buprenorphine prescription for addiction via telehealth

At least 13 dead in Texas as scorching temps continue

Sarepta Duchenne therapy fails to meet primary endpoint in trial

hotspot

The health care issue Democrats can’t solve: hospital reform

The health care issue Democrats can’t solve: hospital reform

Medicare proceeds with plan to claw back hospital funds

Lung cancer screening guidelines updated for cigarette smokers

Explaining an after

Life sciences investors close nearly $6 billion in new funds

knowledge

knowledge

entertainment

focus